整合临床因素、血清标志物与LI-RADS MRI特征的术前列线图预测TACE后肝细胞癌早期复发
结果显示AFP升高、肿瘤较大、边缘不光滑、马赛克结构、卫星结节和晕环强化是独立预测因素,列线图在训练组和测试组的AUC分别为0.94和0.95,校准曲线和决策曲线显示良好拟合和临床获益。
要点
- TACE术前MRI可见边缘不光滑、马赛克结构、卫星结节和晕环强化提示早期复发风险高。
- 整合AFP、肿瘤大小及上述MRI特征的列线图预测TACE后早期复发AUC达0.94-0.95。
- 列线图可用于TACE术前个体化预后评估,辅助临床决策。
英文原文(摘要)· 点击展开
PURPOSE: To develop and validate a preoperative nomogram model that incorporates clinical factors, serological markers and liver imaging reporting and data system (LI-RADS v2018) MRI features for predicting early recurrence (ER) of hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).
METHODS: One hundred and fourteen patients with HCC who underwent MRI scanning before TACE were enrolled retrospectively and divided into a training cohort (n=80) and a test cohort (n=34). The clinical factors, serological markers and LI-RADS v2018 MRI features associated with ER were determined by univariable and multivariable analyses. A nomogram model predicting ER after TACE was developed, and its discriminatory ability, goodness-of-fit and clinical application were evaluated by receiver operating characteristic (ROC) curve, calibration curve and decision curve analysis (DCA), respectively.
RESULTS: In total, 74 (64.9%) patients were diagnosed with ER according to the follow-up results. Increased alpha fetoprotein (AFP) levels, larger tumor size, nonsmooth margin, mosaic architecture satellite nodules and corona enhancement were independent predictors associated with ER (p < 0.05). For the established nomogram model that incorporated these six significant predictors, the AUC values were 0.94 (95% CI: 0.89-0.99) and 0.95 (95% CI: 0.88-1.00) for predicting ER after TACE in the training and test cohorts, respectively. The calibration curve and DCA results demonstrate the good goodness-of-fit and clinical benefits of this nomogram.
CONCLUSION: A preoperative nomogram model based on serological markers and LI-RADS v2018 MRI features could adequately predict ER in HCC patients after TACE, which may provide personalized guidance for predicting prognosis.
引用
- Sheng, Wang, Liu, et al. Preoperative Nomogram Incorporating Clinical Factors, Serological Markers and LI-RADS MRI Features to Predict Early Recurrence of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Acad Radiol. 2022. PMID: 36424310. doi:10.1016/j.acra.2022.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。